drugset / Trial / NCT05212896
An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors
Phase 1
Unknown
90 enrolled
Dragonboat Biopharmaceutical Company Limited
West China Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a first in human, open-label, exploratory phase I clinical study including dose escalation (Ia) and dose expansion (Ib) stage. It aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BC006 in giant cell tumor of tendon sheath (GCTTS) and other advanced solid tumors.
Timeline
- Start
- 2021-11-26
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BC006 | Monoclonal antibody | 0.08 mg/kg | Intravenous |
| Subject | BC006 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | BC006 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | BC006 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | BC006 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | BC006 | Monoclonal antibody | 20 mg/kg | Intravenous |